9,650 Results

FDA accepts sBLA for Tecentriq plus nab-paclitaxel for first line treatment of triple negative breast cancer.- Genentech /Roche

 Added 23 hours ago

Genentech announced the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab)...

FDA gives 510(k) clearance for BD Phoenix CPO detect test to identify carbapenemase-producing organisms- Becton Dickinson

 Added 23 hours ago

Becton, Dickinson and Company announced the FDA has given 510(k) clearance of the BD Phoenix CPO detect test, which will...

Phase IIIb EXPEDITION-8 study of Mavyret shows sustained response in hepatitis C.- AbbVie.

 Added 23 hours ago

AbbVie announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, Mavyret (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated...

FDA accepts sNDA for Gattex for pediatric patients with Short Bowel Syndrome.- Shire plc

 Added 23 hours ago

Shire plc announced that the FDA has accepted for filing the supplemental new drug application to extend the indication of...

AstraZeneca to divest US rights to Synagis to SOBI.

 Added 23 hours ago

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection...

Real-world evidence on patients aged 80 and older presented from ARISTOPHANES study evaluating oral anticoagulants among patients with non-valvular atrial fibrillation- BMS + Pfizer

 Added 2 days ago

The Bristol-Myers Squibb-Pfizer Alliance presented new real-world evidence (RWE) from a sub-analysis of the ARISTOPHANES study comparing the safety and...

Phase III ODYSSEY OUTCOMES trial of Praluent shows fewer deaths from CV events-. Sanofi + Regeneron.

 Added 2 days ago

New analyses on mortality from the 18,924-patient phase III ODYSSEY OUTCOMES trial of Praluent (alirocumab), from Regeneron, shows it is...

Phase III DECLARE-TIMI 58 results for Farxiga show reduced risk of hospitalisation from CV events.- AstraZeneca.

 Added 2 days ago

AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) which showed that...

PIONEER-HF trial of Entresto for heart failure published in NEJM.- Novartis.

 Added 2 days ago

Novartis announced results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto (sacubitril/valsartan) tablets provided superior benefit compared...

NICE does not recommend Lynparza as maintenance treatment for ovarian cancer. AstraZeneca + Merck Inc.

 Added 3 days ago

The National Institute for Health and Care Excellence (NICE) in draft guidance, has recommended against expanding coverage of Lynparza as...

Load more